News | September 12, 2025
A.forall expands US generics portfolio
Four FDA-approved products strengthen portfolio and reaffirm commitment to global reach
Four FDA-approved products strengthen portfolio and reaffirm commitment to global reach
FY26 revenue rises 17% to Rs 5,453 crore as US generics business jumps 49% and adjusted EBITDA margin improves to 26% for the quarter
Analysts expect modest revenue growth but pressure on profitability in the March quarter
The approved product is a generic version of Ravicti, originally developed and marketed by Horizon Therapeutics
The drug is designed to provide temporary relief from cough caused by throat and bronchial irritation
The Abbreviated New Drug Application with FDA covers multiple strengths of Dapagliflozin and Metformin Hydrochloride Extended-Release Tablets
Final approval for progesterone vaginal inserts expands Glenmark’s women’s healthcare portfolio in the US, targeting a market of over $59 million
In just the last few days, companies including Lupin, Biocon, Alembic Pharmaceuticals and Aurobindo Pharma have announced approvals for 5 mg and 10 mg tablets, all bioequivalent to Farxiga
Final approval for diabetes and heart-failure drug opens access to a $10.5 billion US market opportunity, with shared exclusivity benefits.
Tablets will be manufactured at Granules' US-based facility located in Chantilly, Virginia
Subscribe To Our Newsletter & Stay Updated
